From the College of Medicine (Alasiri, Alanazi, Alhnake, Alkahtani), Imam Mohammed Ibn Saud Islamic University, from the Department of Psychiatry (Alahmari), Prince Sultan Military Medical Hospital, and from the Department of Psychiatry (Aljaffer), College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Neurosciences (Riyadh). 2024 Oct;29(4):215-223. doi: 10.17712/nsj.2024.4.20230112.
To assess and evaluate the mental health and psychological changes in weight loss injection users and bariatric surgery.
A descriptive and analytical cross-sectional study was conducted from July 2022 to December 2022. A self-administered questionnaire was given among participants using social media platforms. The questionnaire included socio-demographic characteristics, weight-loss-related characteristics, General Anxiety Disorder (GAD-7) to measure anxiety, and Patient Health Questionnaire (PHQ-9) to measure depression experienced by the patients.
Of the 721 patients, 73.9% were females, and 30.1% were aged between 30 to 39 years old. The prevalence of patients who underwent weight loss by surgery and injection was 47.7% and 41.2%, respectively. Overall, symptoms of anxiety and depression were detected in 19.7% and 24%, respectively. Independent risk factor of anxiety and depression was the symptom of the psychiatric disorder prior to surgery, while the independent protective factor for anxiety and depression was older age. Depression was higher in weight loss injection users.
Nearly one-quarter of the study population experienced anxiety or depression following weight loss treatment. Weight loss treatment by injections increases the risk of depression. However, improved self-confidence, mood, and relationships with family and friends were some of the positive changes exhibited by the patients after undergoing weight loss treatment. Appropriate psychiatric evaluation is necessary before and after weight loss intervention.
评估减肥注射使用者和减重手术患者的心理健康和心理变化。
本研究为 2022 年 7 月至 2022 年 12 月进行的描述性和分析性横断面研究。通过社交媒体平台向参与者发放自填式问卷。问卷包括社会人口统计学特征、与减肥相关的特征、用于测量焦虑的广泛性焦虑障碍（GAD-7）和用于测量患者抑郁的患者健康问卷（PHQ-9）。
在 721 名患者中，73.9%为女性，30.1%年龄在 30 至 39 岁之间。接受手术和注射减肥的患者比例分别为 47.7%和 41.2%。总体而言，焦虑和抑郁症状的检出率分别为 19.7%和 24%。手术前精神障碍症状是焦虑和抑郁的独立危险因素，而年龄较大是焦虑和抑郁的独立保护因素。减肥注射使用者的抑郁发生率更高。
研究人群中有近四分之一在接受减肥治疗后出现焦虑或抑郁。减肥注射治疗会增加患抑郁症的风险。然而，患者在接受减肥治疗后表现出一些积极的变化，如自信心提高、情绪改善以及与家人和朋友的关系改善。在进行减肥干预前后需要进行适当的精神评估。
